Sat, Aug 23, 2014, 12:24 AM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Ohr Pharmaceutical, Inc. Message Board

  • gs88gs88 gs88gs88 Aug 31, 2013 3:32 AM Flag

    Is this an intellictual property violation?

    If you Google Squalamax---someone is pushing oral squalamine capsules. Marketing states it is from "shark liver" and is "natural". It mentions anti-angiogenesis. about $34 for 100 capsules. I assume an IP violation?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • They are selling oil from sharks but the amount of squalamine is infinitesimal, less than 0.01%. Anyway I don't believe that a significant amount of squalaminie can be absorbed by an oral route since the intestinal villi have a outer layer of cells that lie between the lumen and the capillaries and these cells are not going to let a large charged molecule pass through them unless by active transport, which doesn't occur with squalamine.

      • 1 Reply to livermore10
      • Trodusquemine is not charged and is about the same size as squalamine; I think it could be aborbed by an oral route using a sublingual formulation if need be. Here is an abstract from a paper last year on trodusquemine:

        "Trodusquemine (MSI-1436) causes rapid and reversible weight loss in genetic models of obesity. To better predict the potential effects of trodusquemine in the clinic, we investigated the effects of trodusquemine treatment in a murine model of diet-induced obesity (DIO). Trodusquemine suppressed appetite, reduced body weight (BW) in a fat-specific manner, and improved plasma insulin and leptin levels in mice. Screening assays revealed that trodusquemine selectively inhibited protein-tyrosine phosphatase 1B (PTP1B), a key enzyme regulating insulin and leptin signaling. Trodusquemine significantly enhanced insulin-stimulated tyrosine phosphorylation of insulin receptor (IR) β and STAT3, direct targets of PTP1B, in HepG2 cells in vitro and/or hypothalamic tissue in vivo. These data establish trodusquemine as an effective central and peripheral PTP1B inhibitor with the potential to elicit noncachectic fat-specific weight loss and improve insulin and leptin levels."

        Genaera's human trial of trodusquemine was screwed up when they wasted their time doing a study with a subtherapeutic dose of around 6mg IV every 3 days which lowered sugar but not weight. They rolled up the company before having a chance to do a higher dose study using 20mg IV every 3 days but even a higher dose of 30 or 40mg should have been done due to the linear dose response curve of trodusquemine..

        Now suppose trodusquemine could be formulated into a sublingual dose of 100mg twice daily has a bioavailability of 10%; then this would be an effective dose of around 60mg every 3 days. Assuming half if metabolozed by the liver on the first pass, then this is analogous to a 30mg IV every 3 days and that would probably be sufficient to restore insulin and leptin sensitivity.

    • Sorry about the typo. I can't figure out how to edit a posting on the newer yahoo board.

8.16+0.03(+0.37%)Aug 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Keurig Green Mountain, Inc.
NasdaqGSFri, Aug 22, 2014 4:00 PM EDT, Inc
NYSEFri, Aug 22, 2014 4:00 PM EDT